Medline ® Abstract for Reference 2
of 'Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging'
Cancer of the ampulla of Vater: results of a 20-year population-based study.
Benhamiche AM, Jouve JL, Manfredi S, Prost P, Isambert N, Faivre J
Eur J Gastroenterol Hepatol. 2000;12(1):75.
BACKGROUND: Relatively little attention has been given to the epidemiology and management of cancer of the ampulla of Vater.
SETTING: A series of 111 patients with a cancer of the ampulla of Vater diagnosed over a 20-year period (1976-1995) in a well-defined French population was used to analyse its incidence, management and prognosis as well as to determine time trends. Prognosis was determined by using crude and relative survival rates. Factors predictive of survival were also identified using a relative survival model in a multivariate analysis.
RESULTS: Age-standardized incidence rates were 3.8 per 1000000 inhabitants in men and 2.7 per 1000000 inhabitants in women. Incidence increased over time in men from 1.9 during the first period (1976-1980) to 5.9 during the last period (1991-1995). In women, incidence rates remained stable. A resection for cure was performed in 52 cases (48.1%). Overall, 9.9% of these cancers were classified TNM stage I and 54.1% stage IV. There was no significant variation in treatment modalities and in stage at diagnosis over the study period. The overall operative mortality rate was 7.5%. Relative survival rates were 58.9% at 1 year, 30.9% at 3 years and 20.9% at 5 years. Five-year relative survival rates varied from 72.8% in TNM stage I cancers to 6.6% in TNM stage IV cancers. Age, treatment procedure and stage at diagnosis significantly influenced the prognosis of cancer of the ampulla of Vater. In a multivariate analysis, stage at diagnosis remained the major prognostic factor (P<0.01).
CONCLUSIONS: Although its incidence is increasing in men, cancer of the ampulla of Vater remains a rare tumour in both sexes. No improvements in the management and care of patients have been achieved. Further studies are needed to enhance the understanding of this cancer.
Registre Bourguignon des Cancers Digestifs (INSERM CRI 95 05), Facultéde Médecine, Dijon, France. Anne-Marie.Benhamiche@u-bourgogne.fr